Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of HLX22 plus trastuzumab and XELOX versus trastuzumab and XELOX with or without pembrolizumab for first-line HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma
CTR20243366Phase 3Active
- Sponsor
- HyBioPharma
- Start
- Nov 2024
- Modality
- Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of hlx22 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by HyBioPharma. Started Nov 2024; status: active.
02
Drugs
hlx22
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20243366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243366.